Cephalon has submitted an sNDA to the FDA to market Fentora for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate-to-severe intensity, and relatively short duration. According to a study published in the August 2006 issue of The Journal of Pain, as many as  74%of patients with non-cancer chronic pain conditions treated for persistent pain, such as chronic low back and chronic neuropathic p...